Literature DB >> 29387407

Effect on prostate volume following neoadjuvant treatment with an androgen receptor inhibitor monotherapy versus castration plus an androgen receptor inhibitor in prostate cancer patients intended for curative radiation therapy: A randomised study.

Khairul Majumder1,2, Yvonne Brandberg1, Hemming Johansson2, Enrique Castellanos2, Anders Ullén1,2, Bo Lennernäs3, Sten Nilsson1.   

Abstract

To avoid pubic arch interference, prostate cancer patients are treated with neoadjuvant androgen deprivation therapy (ADT) to achieve prostate volume (PV) reduction prior to radiation treatment. The aim of the present randomised study was to compare the effects on PV of two regimens of ADT, an androgen receptor inhibitor monotherapy vs. castration plus an androgen receptor inhibitor. Consecutive patients with non-metastatic prostate cancer were included in a randomised neoadjuvant study, comparing an androgen receptor inhibitor monotherapy vs. castration plus an androgen receptor inhibitor. PV was assessed prior to the start of endocrine neoadjuvant treatment and prior to the start of radiation therapy (RT). PV assessment was performed by transrectal ultrasound. A total of 110 patients were included. Final sample constituted 88 (80%) patients due to lack of PV information. Castration plus an androgen receptor inhibitor was more effective in PV reduction compared with an androgen receptor inhibitor alone (P<0.001). Planning target volume decreased in the combination arm. There was no significant difference in clinical or demographic or length of neoadjuvant hormonal treatment between the groups. Overall, a significantly larger PV reduction was achieved by castration plus androgen receptor inhibitor, as compared with androgen receptor inhibitor monotherapy. The PV reduction, however, appeared not to translate into better health associated quality of life during the subsequently given curative intended combined EBRT and HDR-brachytherapy. Potential differences between these two treatments regarding anti-tumor effects on micro metastatic disease and radiation potentiating effect remains to be addressed in future prospective trials.

Entities:  

Keywords:  hormonal therapy; neo-adjuvant; prostate cancer; prostate volume; radiotherapy

Year:  2017        PMID: 29387407      PMCID: PMC5769271          DOI: 10.3892/mco.2017.1487

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  21 in total

1.  Influence of androgen deprivation therapy on volume of anatomic zones of prostate in patients with prostate cancer using magnetic resonance imaging.

Authors:  Tsutomu Nishiyama; Yoshihiko Tomita; Kota Takahashi
Journal:  Urology       Date:  2004-05       Impact factor: 2.649

2.  Comparability of CT-based and TRUS-based prostate volumes.

Authors:  K R Badiozamani; K Wallner; W Cavanagh; J Blasko
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-01-15       Impact factor: 7.038

3.  Gastrointestinal symptoms after pelvic radiotherapy: role for the gastroenterologist?

Authors:  H Jervoise N Andreyev; Panagiotis Vlavianos; Peter Blake; David Dearnaley; Andrew R Norman; Diana Tait
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-08-01       Impact factor: 7.038

4.  The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate.

Authors:  R Whittington; G A Broderick; P Arger; S B Malkowicz; R D Epperson; B Arjomandy; A Kassaee
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-07-15       Impact factor: 7.038

5.  The choice between a therapy-induced long-term symptom and shortened survival due to prostate cancer.

Authors:  Thomas Hopfgarten; Jan Adolfsson; Lars Henningsohn; Erik Onelöv; Gunnar Steineck
Journal:  Eur Urol       Date:  2006-01-18       Impact factor: 20.096

6.  Definition of the prostate in CT and MRI: a multi-observer study.

Authors:  C Rasch; I Barillot; P Remeijer; A Touw; M van Herk; J V Lebesque
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-01-01       Impact factor: 7.038

7.  Higher sexual interest with androgen receptor inhibitor monotherapy than with castration plus an androgen receptor inhibitor in prostate cancer patients treated with curative radiotherapy, but otherwise small health-related quality of life differences: A randomised prospective 18-month follow-up study.

Authors:  Khairul Majumder; Sten Nilsson; Hemming Johansson; Anders Ullén; Bo Lennernäs; Mia Bergenmar; Yvonne Brandberg
Journal:  Eur J Cancer       Date:  2016-07-25       Impact factor: 9.162

8.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

9.  Long-term symptoms after external beam radiation therapy for prostate cancer with three or four fields.

Authors:  Massoud al-Abany; Asgeir R Helgason; Anna-Karin Agren Cronqvist; Christer Svensson; Peter Wersäll; Gunnar Steineck
Journal:  Acta Oncol       Date:  2002       Impact factor: 4.089

10.  Fate of seminal vesicles and prostate after medical castration: how long is the optimal duration of neoadjuvant treatment for prostate cancer before radiation?

Authors:  Ryoji Furuya; Shin-ichi Hisasue; Seiji Furuya; Nobuhito Saitoh; Hiroshi Ogura; Satoshi Takahashi; Taiji Tsukamoto
Journal:  Urology       Date:  2008-02-11       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.